Quick Answer
Mineralys Therapeutics, Inc. reported Earnings Per Share Diluted of $2.29 (loss) per share for the year ending 2025.
- Mineralys Therapeutics, Inc. showed an increase of +37.4% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Mineralys Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $1.48 (loss) per share | Q2 2022: $1.26 (loss) per share | Q3 2022: $1.29 (loss) per share | Q1 2023: $0.51 (loss) per share | Q2 2023: $0.31 (loss) per share | Q3 2023: $0.57 (loss) per share | Q1 2024: $0.70 (loss) per share | Q2 2024: $0.83 (loss) per share | Q3 2024: $1.13 (loss) per share | Q1 2025: $0.79 (loss) per share | Q2 2025: $0.66 (loss) per share | Q3 2025: $0.52 (loss) per share.
- Over the full 4 years of available data (2022 to 2025), Mineralys Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 60.3%.
- Historical annual values: Fiscal year 2025: $2.29 (loss) per share | Fiscal year 2024: $3.66 (loss) per share | Fiscal year 2023: $1.99 (loss) per share | Fiscal year 2022: $5.77 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: